ClinicalTrials.Veeva

Menu
N

North Carolina Retina Associates | Wake Forest

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tarcocimab
Faricimab
Ranibizumab
OPL-0401
Aflibercept
AVD-104
CT1812

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 7 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

Active, not recruiting
Age Related Macular Degeneration
Drug: HLX04-O
Drug: ranibizumab

This study is researching an experimental drug called aflibercept 8 mg, referred to as "study drug". The study is focused on participants with nAMD a...

Enrolling
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Pro...

Active, not recruiting
Non-Proliferative Diabetic Retinopathy
Drug: Faricimab
Locations recently updated

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerab...

Enrolling
Age-Related Macular Degeneration
Drug: Active Comparator CT1812
Drug: Placebo Comparator

Trial sponsors

A
Cognition Therapeutics logo
H
Kodiak Sciences logo
Regeneron Pharmaceuticals logo
V
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems